Your Messages Inbox
Your Article Summary
See Latest ArticlesXenoPort Reports Positive Results from a Phase 2 Trial of Arbaclofen Placarbil in Spinal Cord Injury Patients with Spasticity
XenoPort, 07/01/09
XenoPort, Inc. announced positive preliminary results from a Phase 2 clinical trial of arbaclofen placarbil, also known as XP19986, for the treatment of patients with spasticity due to spinal cord injury. Doses of 20 and 30 mg of AP, given twice daily, demonstrated statistically significant improvements compared to placebo for the primary endpoint of the study.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Intravenous Drug Administration During Out-of-Hospital Cardiac Arrest: A Randomized Trial
JAMA, 11/25/09
A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimers disease: a post hoc analysis
Current Medical Research and Opinion, 11/25/09
Pandemic 2009 Influenza Update: Pandemrix data in children and adolescents from 3 to 17 years of age
GlaxoSmithKline, 11/24/09
Article Search
Sponsor